Protocol Ledger

NCT04039347 · Phase III · TERMINATED

Extension Trial on Efficacy / Safety of L-CsA + SoC in Treating BOS in Post Single or Double Lung Transplant (BOSTON-3)

Interventional Phase III clinical trial protocol NCT04039347 sponsored by Zambon SpA in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-03-12 Enrollment: 164 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04039347
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)164 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04039347
Protocol FieldVerified Registry Value
NCT IdentifierNCT04039347
Consolidated Lead SponsorZambon SpA
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment164 participants (ACTUAL)
Registered Start Date2020-03-12
WhyStopped ClassificationSafety / Toxicity / Adverse Events

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI